Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.1.7 (
acetylcholinesterase
)
28,390
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The study documented here was aimed to find the molecular interactions of some of the cannabinoid constituents of cannabis with
acetylcholinesterase
(
AChE
). Molecular docking and LogP determination were performed to predict the
AChE
inhibitory effect and lipophilicity.
AChE
enzyme activity was measured in the blood of cannabis addicted human subjects. Further, genetic predisposition to cannabis addiction was investigated by association analysis of cannabinoid receptor 1 (
CNR1
) single nucleotide polymorphism (SNP) rs806368 and
ACHE
rs17228602 using restriction fragment length polymorphism (RFLP) method. All the understudied cannabis constituents showed promising binding affinities with
AChE
and are lipophilic in nature. The
AChE
activity was observed to be indifferent in cannabis addicted and non-addicted healthy controls. There was no significant association with
CNR1
SNP rs806368 and
ACHE
rs17228602. The study concludes that in silico prediction for individual biomolecules of cannabis is different from in vivo physiological action in human subjects when all are present together. However, for a deeper mechanistic insight into these interactions and association, multi-population studies are suggested. Further studies to explore the inhibitory potential of different cannabis constituents for intended
AChE
inhibitor-based drug are warranted.
...
PMID:Cannabis Constituents and Acetylcholinesterase Interaction: Molecular Docking, In Vitro Studies and Association with
CNR1
rs
806368
and
ACHE rs17228602
. 3241 87
